DexCom, Inc.
DXCMHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in. The $29.41B market capitalization puts DXCM squarely in large-cap range for its industry. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Market Cap
$29.41B
Beta
1.48
P/E (TTM)
30.93
P/E (Fwd)
24.95
EPS (TTM)
$2.52
EPS (Fwd)
$3.12
ROE
38.5%
ROA
10.3%
Cash
$1.95B
Total Debt
$1.40B
Free CF
$1.02B
52W Change
10.3%
Annual Financials
Cash vs Debt
Where DXCM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DXCM finished 14.27% above its 150-day moving average ($75.24) and 16.10% above its 200-day moving average ($74.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DXCM overbought or oversold?
At the October 20, 2026 close, DXCM's RSI(14) was 48.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.95B in cash comfortably exceeding the $1.40B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $1.02B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 38.5% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.3% further supports the picture of efficient asset utilization. Revenue has grown from $2.91B (2022) to $4.66B (2025), reflecting a 60% increase over the period.
As with any equity investment, DXCM carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DXCM.